KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Cost of Revenue (2016 - 2025)

AbbVie (ABBV) has disclosed Cost of Revenue for 14 consecutive years, with $4.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 3.55% to $4.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $18.2 billion, a 7.69% increase, with the full-year FY2025 number at $18.2 billion, up 7.69% from a year prior.
  • Cost of Revenue was $4.6 billion for Q4 2025 at AbbVie, down from $5.3 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $6.5 billion in Q3 2023 to a low of $4.0 billion in Q1 2023.
  • A 5-year average of $4.5 billion and a median of $4.3 billion in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: soared 116.94% in 2021, then tumbled 35.05% in 2024.
  • AbbVie's Cost of Revenue stood at $4.3 billion in 2021, then dropped by 3.47% to $4.2 billion in 2022, then soared by 36.79% to $5.7 billion in 2023, then dropped by 22.93% to $4.4 billion in 2024, then increased by 3.55% to $4.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Cost of Revenue are $4.6 billion (Q4 2025), $5.3 billion (Q3 2025), and $4.3 billion (Q2 2025).